CAS: 53-34-9; (6S,8S,9S,10R,11S,13S,14S,17R)-6-Fluoro-11,17-Dihydroxy-17-(2-Hydroxyacetyl)-10,13-Dimethyl-7,8,9,11,12,14,15,16-Octahydro-6H-Cyclopenta[a]Phenanthren-3-One

该化合物是一种该化合物是一种该化合物是一种前硝酮,由于在6α位置引入氟化原子而表现出强化的凝胶受体和同系物的亲和性和代谢稳定性.这一修改改善了它的药理特征,包括比非氟类素的强度增加和作用时间更长. 6a-Fluprednisoroon主要用于研究在炎状和自动免疫条件下的凝胶中间途径和潜在治疗应用.其结构特征使它成为调查甲状腺-受体相互作用和优化以聚氨酸盐为基础的治疗的宝贵工具.该化合物由于生物活动而处于受控制的条件下处理.

结构式图片

上下游产品

CAS号1058-55-5 Pregn-4-ene-3,2...

合成工艺路线路线简述

  • 合成目标产物 Fluprednisolone 主要起始原料 Ethanamine, N-[(3,5-Dichlorophenyl)Methylene]-2,2-Diethoxy-
  • (文献来源)合成步骤主要原料 Ethanamine, N-[(3,5-Dichlorophenyl)Methylene]-2,2-Diethoxy-
📜21-Acetoxy-6α-Fluoro-11β,17-Dihydroxy-Pregn-4-Ene-3,20-Dione置于septomyxa Affinin体系中,化学反应生成 氟泼尼龙
参考文献:Hogg Et Al.,Chemistry And Industry,1958,P. 1002
标题:Hogg Et Al.,Chemistry And Industry,1958,P. 1002

海关参考信息

专利信息


专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:WO-2022226312-A1
优先权日:2021-04-22
标 题:Combination nucleotide pool depletion for treatment of viral infections and cancers
发明人:KUMAR VIKRAM; HESSON DAVID; DEMAREST JAMES
权利人:CLEAR CREEK BIO INC
摘要:The invention provides methods of treating cancers and viral infections by providing a combination of agents that inhibit both nucleotide synthesis and nucleotide salvage in the cells of a subject to prevent cancer proliferation and viral replication. The invention provides methods of depleting nucleotide pools by using both inhibitors of dihydroorotate dehydrogenase (DHODH), such as brequinar, which block synthesis of pyrimidine-based nucleotides, in combination of one or more nucleotide salvage inhibitors, for example deoxycytidine kinase (dCK) inhibitors, Equilibrative nucleoside transporter (ENT) inhibitors, and Uridine-cytidine kinase (UCK) inhibitors, which inhibit salvage of purine and/or pyrimidine-based nucleotides or nucleosides

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-2024287041-A1
优先权日:2021-05-20
标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

专利号:US-11850220-B2
优先权日:2020-05-19
标题 :Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
发明人:PANDA SIVA
权利人:UNIV RES INST INC AUGUSTA
摘要:Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Cho SH, Park JA, Zheng W, Abd El-Aty AM, Kim SK, Choi JM, Yi H, Cho SM, Afifi NA, Shim JH, Chang BJ, Kim JS, Shin HC. Quantification of bupivacaine hydrochloride and isoflupredone acetate residues in porcine muscle, beef, milk, egg, shrimp, flatfish, and eel using a simplified extraction method coupled with liquid chromatography-triple quadrupole tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Oct 15;1065-1066:29-34. doi: 10.1016/j.jchromb.2017.09.026. Epub 2017 Sep 19. doi: 10.1038/eye.2016.243. Epub 2016 Nov 4.
3: Wilson ME, Lambert SR, Plager DA, VanderVeen D, Roarty J, O'Halloran H. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2017 Mar;31(3):506-507. doi: 10.1038/eye.2016.244. Epub 2016 Nov 4.
4: Komori T, Honda T, Irie H, Otsuka A, Kabashima K. Lichen Planus in Irradiated Skin During Nivolumab Treatment. Acta Derm Venereol. 2017 Mar 10;97(3):391-392. doi: 10.2340/00015555-2545. e2. doi: 10.1016/j.ophtha.2016.07.013. Epub 2016 Sep 1.

合成参考文献


参考文献:10.1159/000089030
摘要:Kawada K, Maeda N, Kobayashi S, Sowa J, Tsuruta D, Kawada N. Injection site with generalized rash caused by pegylated interferon alpha 2a injection. Dermatology. 2006;212(1):82–3. doi: 10.1159/000089030.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知